Genotyping by Random Amplified Polymorphic DNA Assay of Acinetobacter baumannii Isolated from Blood Culture of Patients with Hematological Malignancies

Relevance. Acinetobacter baumannii is a significant nosocomial pathogen that can cause severe infections, especially in immunocompromised patients. Aims. This study aimed to investigate clonal diversity of A. baumannii isolated from blood culture in hematological patients by random amplified polymorphic DNA assay (RAPD). Materials & Methods. Genotyping of A.baumannii isolated from blood culture in hematological patients in 7 Russian hospitals (2003–2017) was assessed by RAPD-PCR with primer OPA-2 (5’-TGCCGAGCTG-3’). The computer-assisted analysis was performed by using GelJ software by UPGMA method and Dice similarity coefficient for banding patterns comparison. Using a similarity coefficient (SC) of ≥ 65%, the strains were grouped. Based on the similarity coefficient, the strains were determined as genetically related (≥ 80%). Strains had identical RAPD-patterns if the similarity coefficient was 100%. Results. A total of 96 A. baumannii strains were examined, of those 77 (80.2%) were nonsusceptible to carbapenems. Acquired OXA-carbapenemase genes were detected among 79.2% carbapenem non-susceptible strains. RAPD-PCR genotyping revealed 84 RAPD patterns. The four groups (A-D) including 98% strains were defined by similarity coefficient ≥65%. The predominant group A included 58 (60.4%) strains, the C and B groups – had 15 strains (15.6%) each, and the group D – 6 strains (6.3%). A total of 82 (85.4%) genetically related A. baumannii with a similarity coefficient ≥ of 80% were allocated into 20 clusters. Identical RAPD-patterns were defined for 22 strains that belonged to 6 clusters within the group A and 1 cluster within the group B. Strains with identical RAPD-patterns were detected in a single hospital as well as in several hospitals located in different cities. Conclusions. The current study has demonstrated genetic diversity and clonal dissemination of A. baumannii in hematological departments.

Acinetobacter baumannii, hematological malignancies, blood culture, genotyping, RAPD-PCR, carbapenem resistance, OXA-carbapenemases

1. Gedik H, Simşek F, Kantürk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743–752. https://doi.org/10.2147/tcrm.s68450.

2. Wang X, Zhang L, Sun A, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicenter retrospective study from the Infection Working Party of Jiangsu Society of Hematology. Eur J Clin Microbiol Infect Dis. 2017;36(7):1073–1081. https://doi.org/10.1007/s10096-016-2895-2.

3. Klyasova GА, Speranskaya LL, Mironova АV, et al. The pathogens causing sepsis in immunocompromized patients: structure and problems of antibiotic resistance. Results of a multi-center cooperative study. Gemаtologiya i trаnsfuziologiya. 2007;52(1):3–18 (In Russ).

4. Klyasova GА, Okhmat VА. Antimicrobial therapy. In: Savchenko VG, ed. Algorithms of diagnosing and protocols of treatment of blood system diseases. Moscow: Praktika; 2018:1069–1113 (In Russ).

5. Ballouz T, Aridi J, Afif C, et al. Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia. Front Cell Infect Microbiol. 2017;7:156. https://doi.org/10.3389/fcimb.2017.00156.

6. Freire MP, de Oliveira Garcia D, Garcia C.P., et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:352–358. https://doi.org/10.1016/j.cmi.2015.12.010.

7. Shargian-Alon L, Gafter-Gvili A, Ben-Zvi H, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study. Leuk Lymphoma. 2019;60(11):2787–2792. https://doi.org/10.1080/10428194.2019.1599113.

8. Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol. 2017;7:55. https://doi.org/10.3389/fcimb.2017.00055.

9. Khrulnova SA, Korobova AG, Fyodorova AV, et al. Detection of acquired carbapenemase genes among Acinetobacter baumannii isolated from blood culture in patients with hematological malignancies. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(1):56–60. (In Russ). https://doi.org/10.36488/cmac.2019.1.56-60.

10. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409–1417. https://doi.org/10.1164/rccm.201102-0349oc.

11. Shek EA, Sukhorukova MV, Edelstein MV, et al. Antimicrobial resistance, carbapenemase production, and genotypes of nosocomial Acinetobacter spp. isolates in Russia: results of multicenter epidemiological study «MARATHON 2015–2016». Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):171–80 (In Russ). https://doi.org/10.36488/cmac.2019.2.171-180.

12. Strateva T, Sirakov I, Stoeva T, et al. Carbapenem-resistant Acinetobacter baumannii: Current status of the problem in four Bulgarian university hospitals (2014-2016). J Glob Antimicrob Resist. 2019;16:266–273. https://doi.org/10.1016/j.jgar.2018.10.027.

13. Evans BA, Amyes SG. OXA β-lactamases. Clin Microbiol Rev. 2014;27:241–263. https://doi.org/10.1128/cmr.00117-13.

14. Munoz-Price LS, Namias N, Cleary T, et al. Acinetobacter baumannii: association between environmental contamination of patient rooms and occupant status. Infect Control Hosp Epidemiol. 2013;34(5):517–20. https://doi.org/10.1086/670209.

15. Morgan DJ, Liang SY, Smith CL, et al. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol. 2010;31(7):716–21. https://doi.org/10.1086/653201.

16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement. CLSI document M100-S28. Wayne, PA: Clinical and Laboratory Standarts Institute; 2018.

17. Dahdouh E, Gómez-Gil R, Sanz S, et al. A novel mutation in pmrB mediates colistin resistance during therapy of Acinetobacter baumannii. Int J Antimicrob Agents. 2017;49(6):727–733. https://doi.org/10.1016/j.ijantimicag.2017.01.031.

18. Heras J, Domínguez C, Mata E, et al. GelJ – a tool for analyzing DNA fingerprint gel images. BMC Bioinformatics. 2015;16:270. https://doi.org/10.1186/s12859-015-0703-0

19. Hunter PR. Reproducibility and indices of discriminatory power of microbial typing methods. J Clin Microbiol. 1990;28(9):1903–1905. https://doi.org/10.1128/jcm.28.9.1903-1905.1990.

20. Gordinskaya NA, Sabirova EV, Abramova NV et al. Antibiotics sensitivity and molecular mechanisms of resistance of Acinetobacter baumanii, infectious agents of burn-wound infection. Medicinskij almanah. 2015; 5(40):99–101 (In Russ).

21. Mayanskiy N, Chebotar I, Alyabieva N, et al. Emergence of the Uncommon Clone ST944/ST78 Carrying blaOXA-40-like and blaCTX-M-like Genes Among Carbapenem-Nonsusceptible Acinetobacter baumannii in Moscow, Russia. Microb Drug Resist. 2017;23(7):864–870. https://doi.org/10.1089/mdr.2016.0302.

22. Alsultan AA, Aboulmagd E, Evans BA, et al. Clonal diversity of Acinetobacter baumannii from diabetic patients in Saudi Arabian hospitals. J Med Microbiol. 2014;63(11):1460–66. https://doi.org/10.1099/jmm.0.079640-0.